225382-64-9 Usage
Chemical composition
Consists of a thieno[3,2-b]pyridine group, an imidazol-2-yl group, and a propan-2-ol group.
Derivatives
A derivative of the indole and imidazole chemical classes.
Biological activities
Possesses various biological activities, including potential use as a pharmacological agent or drug.
Methyl substitution
Has a methyl group substitution on both the indole and thieno[3,2-b]pyridine rings, which may affect its biological activity and pharmacokinetics.
Solubility and metabolic properties
The presence of the propan-2-ol group suggests potential solubility and metabolic properties relevant for pharmaceutical use.
Value in medicinal chemistry
The complex structure and diverse functional groups indicate that it could be a valuable compound for further study and development in the field of medicinal chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 225382-64-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,2,5,3,8 and 2 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 225382-64:
(8*2)+(7*2)+(6*5)+(5*3)+(4*8)+(3*2)+(2*6)+(1*4)=129
129 % 10 = 9
So 225382-64-9 is a valid CAS Registry Number.
225382-64-9Relevant academic research and scientific papers
Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
-
, (2008/06/13)
The invention relates to compounds of the formulas 1 and 2 and to pharmaceutically acceptable salts and hydrates thereof, wherein X1, R1, R2and R11are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formulas 1 and 2 and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formulas 1 and 2.
Thiophene derivatives useful as anticancer agents
-
, (2008/06/13)
The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts and hydrates thereof, wherein X, Y, R1, R2 and R11 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula 1.
